MUMBAI, India, Sept. 12 -- Intellectual Property India has published a patent application (202517078966 A) filed by Janssen Pharmaceutica NV, Beerse, Belgium, on Aug. 20, for '2-(pyridazin-3-yl)-5-(trifluoromethyl)phenols as nlrp3 inhibitors.'
Inventor(s) include Mammoliti, Oscar; Jerhaoui, Soufyan; Perez Benito, Laura; Caellas Roman, Santiago; Oehlrich, Daniel; Prieri, Marion Laurence Christiane; Muratore, Michael Eric; and Riccioli, Riccardo.
The application for the patent was published on Sept. 12, under issue no. 37/2025.
According to the abstract released by the Intellectual Property India: "Provided are compounds for use as inhibitors of the NLRP3 inflammasone pathway, wherein such compounds are as defined by compounds of formula (I) and wherein the radicals R1, R2, R3 and Z are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity."
The patent application was internationally filed on Jan. 26, 2024, under International application No.PCT/EP2024/051978.
Disclaimer: Curated by HT Syndication.
